Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Rev Med Suisse ; 19(850): 2165-2171, 2023 Nov 15.
Artigo em Francês | MEDLINE | ID: mdl-37966148

RESUMO

Lung cancer is responsible for one in five cancer-related deaths. Screening for lung cancer using low-dose chest CT (LDCT) is supported by several international studies targeting the at-risk population as part of an organised programme. Given the organisational challenges for the healthcare systems of the countries concerned, this involves setting up pilot screening projects. This requires close collaboration between the players involved, with a multidisciplinary approach structured around the participant, aiming to offer the expertise of the pulmonologist and the radiologist on the LDCT performed, interpreted with the help of artificial intelligence. Here we set out the elements needed to develop a screening programme, starting with the implementation of a pilot project.


Le cancer pulmonaire est responsable d'un décès lié au cancer sur cinq. Le dépistage du cancer pulmonaire par le scanner thoracique à faible dose (LDCT) est soutenu par plusieurs études internationales ciblant la population à risque dans le cadre d'un programme organisé. Vu les enjeux organisationnels pour le système de santé des pays concernés, cela passe par la mise en place de projets pilotes de dépistage. Cela requiert une collaboration étroite entre les différents acteurs, avec une approche multidisciplinaire structurée autour du participant visant à offrir l'expertise du pneumologue et du radiologue sur le LDCT effectué, interprété avec l'aide de l'intelligence artificielle. Nous exposons ici les éléments nécessaires à l'élaboration d'un programme de dépistage, en passant d'abord par la mise en place d'un projet pilote.


Assuntos
Detecção Precoce de Câncer , Neoplasias Pulmonares , Humanos , Programas de Rastreamento , Projetos Piloto , Suíça/epidemiologia , Inteligência Artificial , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/epidemiologia
2.
Transpl Infect Dis ; 25(5): e14151, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37746723

RESUMO

Available data are limited concerning long-term lung function (LF) evolution after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant (LT) recipients. The aim of this study is to determine the effect of first SARS-CoV-2 infection on long-term LF in LT recipients. We analyzed spirometry results of LT recipients followed at our institution (March 2020 to July 2022) at 3, 6, and 12 months after first SARS-CoV-2 infection. Overall, 42 LT patients of our cohort (70%) with COVID-19 were included for long-term LF analysis. Forced expiratory volume in 1 s (FEV1 ) declined significantly at 3 months (-4.5%, -97 mL, 95% CI [-163; -31], p < .01), but not at 6 and 12 months (-3.9%, -65 mL, 95% CI [-168; +39], p = .21). Results were quite similar for the forced vital capacity. Spirometry values declined significantly at 3 months after COVID-19 in LT recipients, presented a mixed decline at 6 months, and no significant decline at 12 months.


Assuntos
COVID-19 , Transplante de Pulmão , Humanos , Transplante de Pulmão/efeitos adversos , Transplantados , Estudos Retrospectivos , SARS-CoV-2 , Pulmão
3.
ERJ Open Res ; 9(5)2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37701366

RESUMO

Background: Recent evidence identified exposure to particulate matter of size ≤2.5 µm (PM2.5) as a risk factor for high prevalence of small airway dysfunction (SAD). We assessed the prevalence of SAD in a European region with low air pollution levels. Methods: SAD was defined as a maximum mid-expiratory flow (MMEF) <65% of predicted value (PV) or MMEF 65 years only. In an area where ambient PM2.5 concentration was <15 µg·m-3 during the observation period (2010 and 2020), ≥72% of participants with SAD were ever-smokers. Conclusions: The observed low prevalence of SAD of 5.0-12.7% depending on criteria employed may be related to lower PM2.5 exposure. Smoking was the main factor associated with SAD in an area with low PM2.5 exposure. Employing a MMEF threshold <65% PV carries a risk of SAD overdiagnosis in elderly individuals.

4.
Rev Med Suisse ; 19(821): 674-679, 2023 Apr 05.
Artigo em Francês | MEDLINE | ID: mdl-37017349

RESUMO

Within the group of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides, granulomatosis with polyangiitis (GPA) is the most frequent. The incidence is around 10 to 20 cases/million/year. Clinical manifestations are varied, with ENT, lungs and kidneys most frequently involved. ANCA are pathogenic by triggering neutrophil activation, which leads to vascular damage. Detection of ANCA is most helpful in establishing the diagnosis, but serology may be negative in GPA limited to the airways. Diagnostic work-up and therapy require a multidisciplinary approach. Treatment includes an induction and maintenance phase, combining corticosteroids and immunosuppressive drugs. It aims at limiting the risk of relapses, which is important in GPA, and at reducing corticosteroids toxicity.


La granulomatose avec polyangéite (GPA) fait partie des vasculites associées aux anticorps anti-cytoplasme des polynucléaires neutrophiles (ANCA). La maladie touche principalement la sphère ORL, les poumons et les reins. Son incidence est de 10 à 20 cas/million/année. Les ANCA sont pathogéniques en induisant une activation des polynucléaires neutrophiles, entraînant des lésions endothéliales. Le diagnostic est facilité par la détection des ANCA, qui peuvent cependant être absents dans les formes ORL limitées. La prise en charge est multidisciplinaire. Le traitement comprend une phase d'induction et une autre de maintien de la rémission, associant corticostéroïdes et immunosuppresseurs. L'objectif du traitement est de limiter le risque important de rechute et de réduire la toxicité des corticostéroïdes.


Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos , Granulomatose com Poliangiite , Humanos , Granulomatose com Poliangiite/diagnóstico , Granulomatose com Poliangiite/terapia , Granulomatose com Poliangiite/complicações , Anticorpos Anticitoplasma de Neutrófilos/uso terapêutico , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/terapia , Imunossupressores/uso terapêutico , Corticosteroides/uso terapêutico
5.
Rev Med Suisse ; 18(804): 2134-2142, 2022 Nov 16.
Artigo em Francês | MEDLINE | ID: mdl-36382973

RESUMO

Despite technical improvements concerning lung irradiation modalities, radiation-induced pneumonitis remains a usual complication, notably in the field of lung cancer treatment. This complication may remain asymptomatic but can also lead to respiratory distress. Thus, a low degree of suspicion and a comprehensive work-up is mandatory to evaluate the indication for specific treatment. In this article, we discuss the hypothesized pathophysiologic pathways, risk factors, clinical/radiological presentation and management.


Malgré les améliorations des techniques d'irradiation à l'étage thoracique, la pneumopathie radique (PpR) reste une complication fréquente, en particulier dans le cadre du traitement du cancer pulmonaire. Cette complication, qu'elle soit précoce ou tardive, peut demeurer silencieuse ou causer une détresse respiratoire potentiellement fatale. C'est pourquoi un faible degré de suspicion est nécessaire, de manière à débuter précocement un bilan d'investigation et décider de l'indication à un traitement spécifique. Dans cet article, nous discutons des hypothèses pathophysiologiques qui sous-tendent la PpR, des facteurs de risque de survenue, de la présentation clinique et radiologique, ainsi que de sa prise en charge.


Assuntos
Neoplasias Pulmonares , Pneumonia , Pneumonite por Radiação , Humanos , Pneumonite por Radiação/diagnóstico , Pneumonite por Radiação/epidemiologia , Pneumonite por Radiação/etiologia , Neoplasias Pulmonares/radioterapia , Pulmão , Fatores de Risco , Pneumonia/diagnóstico , Pneumonia/epidemiologia , Pneumonia/etiologia
6.
Rev Med Suisse ; 15(634): 146-148, 2019 Jan 09.
Artigo em Francês | MEDLINE | ID: mdl-30657265

RESUMO

2018 has continued to bring important progress in all areas of internal medicine, impacting our daily practice. From bezafibrate in primary biliary cholangitis to the new Clostridioides difficile guidelines, passing by use of procalcitonine, cristalloids, copeptin and how to administer furosemide, internal medicine journals are full of novelties. Every year, the chief residents of the CHUV internal medicine ward meet up to share their readings : here is their selection of 12 articles, chosen, summarized and commented for you.


L'année 2018 a vu d'importants progrès dans tous les domaines de la médecine interne, avec un impact important sur notre pratique quotidienne. Du bézafibrate dans la cholangite biliaire primitive aux nouvelles recommandations pour le traitement du Clostridioides difficile en passant par l'utilisation de la procalcitonine, des cristalloïdes, de la copeptine et du mode d'administration du furosémide, les nouveautés abondent dans la littérature. Chaque année, les chefs de clinique du Service de médecine interne du Centre hospitalier universitaire vaudois (CHUV) se réunissent pour partager leurs lectures : voici une sélection de 12 articles choisis, revus et commentés pour vous.


Assuntos
Medicina Interna , Medicina Interna/tendências , Editoração
7.
JACC Cardiovasc Imaging ; 5(12): 1231-9, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23236973

RESUMO

OBJECTIVES: This study sought to establish an accurate and reproducible T(2)-mapping cardiac magnetic resonance (CMR) methodology at 3 T and to evaluate it in healthy volunteers and patients with myocardial infarct. BACKGROUND: Myocardial edema affects the T(2) relaxation time on CMR. Therefore, T(2)-mapping has been established to characterize edema at 1.5 T. A 3 T implementation designed for longitudinal studies and aimed at guiding and monitoring therapy remains to be implemented, thoroughly characterized, and evaluated in vivo. METHODS: A free-breathing navigator-gated radial CMR pulse sequence with an adiabatic T(2) preparation module and an empirical fitting equation for T(2) quantification was optimized using numerical simulations and was validated at 3 T in a phantom study. Its reproducibility for myocardial T(2) quantification was then ascertained in healthy volunteers and improved using an external reference phantom with known T(2). In a small cohort of patients with established myocardial infarction, the local T(2) value and extent of the edematous region were determined and compared with conventional T(2)-weighted CMR and x-ray coronary angiography, where available. RESULTS: The numerical simulations and phantom study demonstrated that the empirical fitting equation is significantly more accurate for T(2) quantification than that for the more conventional exponential decay. The volunteer study consistently demonstrated a reproducibility error as low as 2 ± 1% using the external reference phantom and an average myocardial T(2) of 38.5 ± 4.5 ms. Intraobserver and interobserver variability in the volunteers were -0.04 ± 0.89 ms (p = 0.86) and -0.23 ± 0.91 ms (p = 0.87), respectively. In the infarction patients, the T(2) in edema was 62.4 ± 9.2 ms and was consistent with the x-ray angiographic findings. Simultaneously, the extent of the edematous region by T(2)-mapping correlated well with that from the T(2)-weighted images (r = 0.91). CONCLUSIONS: The new, well-characterized 3 T methodology enables robust and accurate cardiac T(2)-mapping at 3 T with high spatial resolution, while the addition of a reference phantom improves reproducibility. This technique may be well suited for longitudinal studies in patients with suspected or established heart disease.


Assuntos
Circulação Coronária/fisiologia , Imagem Cinética por Ressonância Magnética/métodos , Infarto do Miocárdio/diagnóstico , Miocárdio/patologia , Imagens de Fantasmas , Adulto , Estudos de Viabilidade , Feminino , Humanos , Masculino , Infarto do Miocárdio/fisiopatologia , Curva ROC , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...